In response, the PDA formed a dedicated task force. This group, composed of experts from regulatory bodies (including the FDA), major pharma companies (Amgen, Genentech, Pfizer), and reagent manufacturers (Lonza, Charles River), worked for over four years to standardize the understanding of LER. Their work culminated in (2018).
Review all marketed and pipeline parenteral products. Flag any containing polysorbates (20 or 80), Cremophor, cyclodextrins, or EDTA. pda technical report 82
In the world of parenteral drug manufacturing, ensuring sterility and safety is paramount. While the compendial bacterial endotoxins test (BET), often regulated by USP <85> and EP 2.6.14, has been the gold standard for decades, the industry has faced a perplexing and potentially dangerous phenomenon: Low Endotoxin Recovery (LER) . In response, the PDA formed a dedicated task force
PDA TR 82 fundamentally changed the paradigm from "Does the test pass?" to "Does the test remain valid throughout the shelf-life of the sample?" Conclusion: Why You Must Read PDA TR 82 If you work in Quality Control, Process Development, or Regulatory Affairs for sterile injectable drugs, PDA Technical Report 82 is not optional reading—it is essential. Review all marketed and pipeline parenteral products
The report demystifies a complex colloidal phenomenon and provides a practical, risk-based framework to protect patients from masked endotoxin. It acknowledges that no test is perfect, but through aggressive investigation and mitigation, we can close the safety gap.
Furthermore, the industry is moving toward . Instead of just testing the final product, manufacturers are using real-time bioburden monitoring and endotoxin removal chromatography to eliminate LER risk at the source.